한빛사논문
- 조회146
질병관리청
Yoo-Yeon Kim,1 Young June Choe,1 Jia Kim, Ryu Kyung Kim, Eun Jung Jang, Seon Kyeong Park, Do-Sang Lim, Seonju Yi, Sangwon Lee, Geun-Yong Kwon,
Jee Yeon Shin, Sang-Yoon Choi, Mi Jin Jeong, Young-Joon Park
Korea Disease Control and Prevention Agency, Cheongju, South Korea (Y.-Y. Kim, J. Kim, R.K. Kim, E.J. Jang, S.K. Park, D.-S. Lim, S. Yi, S. Lee, G.-Y. Kwon, J.Y. Shin, S.-Y. Choi, M.J. Jeong, Y.-J. Park); Korea University Anam Hospital, Seoul, South Korea (Y.J. Choe)
1These authors contributed equally to this article.
Correspondence: Young-Joon Park
Abstract
We used a nationwide population registry in South Korea to estimate the effect of a second booster dose of mRNA COVID-19 vaccine on the risk for laboratory-confirmed SARS-CoV-2 infection, critical infection, and death in immunocompromised persons and long-term care facility (LTCF) residents. During February 16–May 7, 2022, among 972,449 eligible persons, 736,439 (75.7%) received a first booster and 236,010 (24.3%) persons received a second booster. Compared with the first booster group, at 30–53 days, the second booster recipients had vaccine effectiveness (VE) against all infections of 22.28% (95% CI 19.35%–25.11%), VE against critical infection of 56.95% (95% CI 29.99%–73.53%), and VE against death of 62.96% (95% CI 34.18%–79.15%). Our findings provide real-world evidence that a second booster dose of mRNA vaccine substantially increases protection against critical infection and death in these high-risk population groups.
논문정보
- Research article
- 2022년 11월 (BRIC 등록일 2023-01-16)
- 국내 연구진
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
